Mirum Pharmaceuticals, Inc. (MIRM) Prices 2.4M Share Common Offering at $20/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- First Financial to acquire Hickory Point Bank in $111.3M deal
Mirum Pharmaceuticals Announces Pricing of Public Offering
January 8, 2020 8:15 PM ESTFOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing of its public offering of 2,400,000 shares of its common stock at a price to the public of $20.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $48.0 million.
In addition, Mirum has granted the underwriters a 30-day option to purchase up to an additional 360,000... More
